X0306 4 2021-10-25 0 0001851194 Ventyx Biosciences, Inc. VTYX 0001727703 Royston Aaron C/O VENTYX BIOSCIENCES, INC. 662 ENCINITAS BLVD, SUITE 250 ENCINITAS CA 92024 1 0 1 0 Common Stock 2021-10-25 4 C 0 3684769 0.00 A 3684769 I See footnote Common Stock 2021-10-25 4 P 0 312500 16.00 A 3997269 I See footnote Common Stock 1014267 I See footnote Series A Preferred Stock 2021-10-25 4 C 0 3289742 0.00 D Common Stock 3289742 0 I See footnote Series B Preferred Stock 2021-10-25 4 C 0 395027 0.00 D Common Stock 395027 0 I See footnote All shares of the preferred stock, par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. Shares held by venBio III. venBio GP is the sole general partner of venBio III. venBio Ltd is the sole general partner of venBio GP. The Reporting Person, Robert Adelman and Corey Goodman are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the shares held by venBio III. The Reporting Person disclaims beneficial ownership over the shares held by venBio III except to the extent of his pecuniary interest therein. Shares held by venBio SPV III, LLC ("venBio SPV"). venBio SPV is wholly owned and managed by venBio Global Strategic Fund III, L.P. ("venBio III"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership ("venBio GP") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company ("venBio Ltd") is the sole general partner of venBio GP. The Reporting Person, Robert Adelman and Corey Goodman are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the shares held by venBio SPV. The Reporting Person disclaims beneficial ownership over the shares held by venBio SPV except to the extent of his pecuniary interest therein. /s/ Christopher Krueger, as Attorney-in-Fact 2021-10-25